VistaGen Therapeutics Q3 EPS $(0.22) Beats $(0.30) Estimate, Sales $411.40K Miss $544.50K Estimate
VistaGen Therapeutics Q3 EPS $(0.22) Beats $(0.30) Estimate, Sales $411.40K Miss $544.50K Estimate
VistaGen Therapeutics第三季度每股收益美元（0.22美元）超过预期（0.30美元），销售额为411.4万美元，低于预期的544.5万美元
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.30) by 26.67 percent. This is a 84.51 percent increase over losses of $(1.42) per share from the same period last year. The company reported quarterly sales of $411.40 thousand which missed the analyst consensus estimate of $544.50 thousand by 24.44 percent. This is a 129.06 percent increase over sales of $179.60 thousand the same period last year.
VistaGen Therapeutics（纳斯达克股票代码：VTGN）公布的季度亏损为每股0.22美元，比分析师共识估计的美元（0.30美元）高出26.67％。与去年同期每股亏损1.42美元（1.42）相比，增长了84.51％。该公司公布的季度销售额为411,400美元，比分析师普遍预期的544,500美元低24.44％。这比去年同期的179,600美元的销售额增长了129.06％。